Excellos, Cell Therapy Contract And Development Manufacturing Organization Member Of Blood Centers Of America Has Been Selected To Manufacture Galapagos' Car-t Cell Therapy Candidate, GLPG5101, For Its Recently FDA-Cleared ATALANTA-1 Study For Relapsed/Refractory Non-Hodgkin Lymphoma
Portfolio Pulse from Benzinga Newsdesk
Excellos has been chosen to manufacture Galapagos' CAR-T cell therapy candidate, GLPG5101, for the ATALANTA-1 study targeting relapsed/refractory non-Hodgkin lymphoma. This follows FDA clearance for the study.
October 01, 2024 | 10:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Galapagos has selected Excellos to manufacture its CAR-T cell therapy candidate, GLPG5101, for a study on non-Hodgkin lymphoma, following FDA clearance.
The selection of Excellos to manufacture GLPG5101 for an FDA-cleared study is a positive development for Galapagos, indicating progress in their CAR-T cell therapy program. This could lead to increased investor confidence and potential stock price appreciation.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80